Neoadjuvant chemotherapy

March 25, 2020March 25, 2020

GEN-1 Added to Chemo Improves Removal of Ovarian Tumors, Early Data Show

News

The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant chemotherapy ... Read more

March 18, 2019

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

News

Adding Celsion‘s GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during surgery, ... Read more

October 4, 2017

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

News

All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who ... Read more

August 30, 2017

Celsion to Present New Data from OVATION Trial at Ovarian Cancer Meeting

News

All newly diagnosed ovarian cancer patients enrolled in the OVATION Phase 1b trial (NCT02480374) to date benefited from the addition of GEN-1 to standard of care, according to Celsion, the drug’s developer. ... Read more

July 7, 2017July 7, 2017

Celsion’s GEN-1 Combined with Chemotherapy May Help Treat Advanced Ovarian Cancer

News

Interim results of a clinical trial evaluating Celsion’s GEN-1 combined with preoperative chemotherapy to treat patients with advanced ovarian cancer were recently presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting. The ... Read more

January 23, 2017January 24, 2017

GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients

News

Combining the DNA-based immunotherapy GEN-1 with standard of care neoadjuvant chemotherapy continues to show promise in patients with newly-diagnosed advanced ovarian cancer who will undergo interval debulking surgery, according to ... Read more

September 21, 2016

Careful Selection of Ovarian Cancer Patients for Chemo Before Surgery May Improve Survival Rates

News

The use of neoadjuvant chemotherapy (NACT), or chemo administered before surgery, in patients with ovarian cancer has increased as an alternative to primary cytoreductive surgery (PCS), performed when a woman ... Read more

August 15, 2016August 15, 2016

New Guidelines for First-Line Chemo Against Advanced Ovarian Cancer Issued

News

According to a new clinical guideline jointly created by the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology, some women with advanced ovarian cancer should receive neoadjuvant chemotherapy as ... Read more